A Randomized Two Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phae or in Myeloid or Lymphoid

  • McDonagh, Kevin (PI)

Grants and Contracts Details

Effective start/end date11/1/0510/31/13